By visiting our website or using services provided by Sai Life Sciences, you are accepting the practices described in the Privacy Policy.

We also use cookies on our websites. Cookies allow us to give you the best browsing experience and help us to understand how you use our site. You can disable cookies but parts of our website may not work. By continuing to use this website, you agree that we may store and access cookies on your device.

By clicking “I Accept”, you confirm that you are above the age of 16, that you have read and understood the Cookies Usage and the Privacy Policy, and that you agree to the collection, use and processing of your Personal Information by Sai Life in accordance with said policies.

I accept

Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2021.09.14

Sai Life Sciences achieves EcoVadis Silver for Sustainability

Sai Life Sciences achieves EcoVadis Silver for Sustainability

In a global assessment acknowledged as a gold standard by procurers and suppliers, winning a silver is gratifying. With a net score of 57, nine points higher than last year, Sai Life Sciences has reaffirmed its commitment to social, economic and environmental responsibility in the evaluation by EcoVadis, the world’s most trusted provider of business sustainability ratings.

Numerous factors contributed to Sai Life Sciences moving from Bronze last year to Silver this year:

- Publication of first sustainability report
- ISO certification
- Endorsement of external initiatives such as Pharmaceutical Supply Chain Initiative (PSCI) and ACS Green Chemistry Institute - Pharmaceutical Roundtable
- Sustainable Development Goals (SDGs)
- Comprehensive policy for all sustainability aspects

The EcoVadis Rating covers a broad range of criteria on non-financial management system indices including Environmental, Labor & Human Rights, Ethics and Sustainable Procurement. In the Environment parameter, our score increased from 50 to 70, and from 50 to 60 in Labor & Human Rights.

As a a firm believer in continual improvement, we will focus on strategic initiatives to upgrade our rating to the next level in the year ahead.

Share article

More News

2026.03.27

Inside Sai Life Sciences’ Integrated R&D Campus: Accelerating Drug Development

In a recent feature published in R&D World, Sai Life Sciences’ Integrated R&D Campus in Hyderabad is showcased as a model for accelerating drug discovery and development through true scientific integration.In the article, Dr. B.V.N.B.S. Sarma, Senior Vice President – Discovery, highlights how co-locating multidisciplinary teams—from medicinal chemistry and biology to DMPK, developability, process development, […]
Read more

2026.03.27

Sai Life Sciences hosts Biotech Pitch Day 2026 at Boston Site

Sai Life Sciences successfully hosted its Biotech Pitch Day 2026 at its Boston-area site on March 19, bringing together a dynamic group of emerging biotech innovators, scientific leaders, and industry experts. The event was designed as a platform for early-stage biotech companies to showcase their science, strengthen visibility, and engage with potential collaborators across the […]
Read more

2026.03.25

Kudikunta Lake restoration completed, marking the revival of an urban water body

Kudikunta Lake in Kondapur, Hyderabad, was inaugurated on February 28th following the completion of restoration efforts undertaken by Sai Life Sciences as part of its Corporate Social Responsibility (CSR) initiative in collaboration with the Society for Advancement of Human Endeavour (SAHE). The event marked the culmination of several months of work to restore a previously […]
Read more

2026.03.10

AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery. Retrosynthesis is a […]
Read more

2026.03.10

Structural Biology capabilities launched with X-Ray Crystallography

Sai Life Sciences has introduced integrated structural biology capabilities with the establishment of X-ray protein crystallography workflows to support structure-based drug discovery programs. The platform encompasses end-to-end protein engineering capabilities, including construct design, gene synthesis, and in-house recombinant protein expression and purification. These foundational steps enable generation of high-quality protein material suitable for structural and […]
Read more